Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UCB's Neupro (rotigotine transdermal system) showed greater improvement in early morning motor symptoms and sleep quality, compared with placebo, and as measured by the Unified Parkinson's Disease Rating Scale and the Parkinson's Disease Sleep Scale.
Subscribe to our email newsletter
UCB has released new data on Neupro, at the 14th International Congress of Parkinson’s Disease and Movement Disorders in Buenos Aires, Argentina,
Neupro’s clinical data is investigated through a multicentre, multinational, double-blind, placebo-controlled study, known as the Recover study, designed to assess the effects of rotigotine in controlling early morning motor function and non-motor symptoms that affect the everyday lives of people with Parkinson’s disease.
The co-primary efficacy endpoints of Recover study were the mean change from baseline to end of maintenance in Parkinson’s Disease Sleep Scale (PDSS-2) and Unified Parkinson’s Disease Rating Scale (UPDRS) Part III scores.
Claudia Trenkwalder from the Paracelsus-Elena Hospital, Kassel, Germany, said: “Sleeping without being restless, uncomfortable or immobile during the night may be just as important to people with Parkinson’s disease, as being able to move around during the day.
“Findings from the Recover study showed that rotigotine was an effective treatment option for patients with Parkinson’s disease having beneficial effects on both motor and non-motor symptoms.”